Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1s are practically everywhere – roughly one in eight U.S. adults take one. But stopping those drugs may come at a cost. That's according to a new study from the Washington University School of Medicine, which was published on Wednesday in BMJ Medicine. The research found that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes, and the impact may not be fully reversible. Using electronic health records, researchers followed more than 333,000 adults with diabetes over three years, and the lion's share of them were taking Novo Nordisk 's diabetes injection Ozempic. Here are the key data points: Patients who stayed on GLP-1s over three years saw an 18% reduction in cardiovascular risk Quitting GLP-1s for as lit
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India [Yahoo! Finance]Yahoo! Finance
- Ozempic Is About to Go Generic in India, China and Canada [The New York Times]The New York Times
- Novo Nordisk Obesity Drug Data Sparks Questions On Valuation And Momentum [Yahoo! Finance]Yahoo! Finance
- Analysis-TrumpRx lists many medicines at prices higher than paid in UK [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $175.00 price target on the stock.MarketBeat
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website